Featured Research

from universities, journals, and other organizations

Optimal treatment duration for MRSA-related pneumonia re-evaluated

Date:
October 20, 2012
Source:
Henry Ford Health System
Summary:
The U.S. national practice guideline for treating MRSA-related pneumonia is seven to 21 days. A new study found that effective treatment can be done in half the time. Researchers found that 40 percent of patients were treated for eight to 13 days on a therapy of the antibiotics vancomycin or linezolid, and had the highest survival rate.

The national practice guideline for treating MRSA-related pneumonia is seven to 21 days. A Henry Ford Hospital study found that effective treatment can be done in half the time.

Related Articles


Researchers found that 40 percent of patients were treated for eight to 13 days on a therapy of the antibiotics vancomycin or linezolid, and had the highest survival rate.

The Henry Ford study is believed to be the first to evaluate the length of treatment for MRSA-related pneumonia.

The study is being presented October 19 at the annual Infectious Diseases Society of America meeting in San Diego.

"Based on our study, clinicians can effectively treat their patients within eight to 13 days, thus minimizing patients' exposure to antibiotics and their side effects," says Hadeel Zainah, M.D., a second-year Infectious Diseases fellow at Henry Ford and the study's lead author.

MRSA-related pneumonia is a respiratory illness that typically follows a bout of the flu. Symptoms include a cough, sore throat, head ache, shortness of breath, fever and chills.

In the retrospective study, researchers evaluated the medical charts of 115 patients hospitalized with MRSA pneumonia. Patients received either vancomycin or linezolid, or both.

Of the 115 patients, 32 died after 28 days.

Other findings:

• 27 percent of patients were treated for 14-20 days.

• 13.9 percent of patients were treated for more than 20 days.

• These treatment durations had lower survival rates than the eight to 13 days.

Researchers did not evaluate whether the treatment duration affected length of stay or whether one antibiotic fared better than the other.

The study was funded by Henry Ford Hospital.


Story Source:

The above story is based on materials provided by Henry Ford Health System. Note: Materials may be edited for content and length.


Cite This Page:

Henry Ford Health System. "Optimal treatment duration for MRSA-related pneumonia re-evaluated." ScienceDaily. ScienceDaily, 20 October 2012. <www.sciencedaily.com/releases/2012/10/121020162448.htm>.
Henry Ford Health System. (2012, October 20). Optimal treatment duration for MRSA-related pneumonia re-evaluated. ScienceDaily. Retrieved November 26, 2014 from www.sciencedaily.com/releases/2012/10/121020162448.htm
Henry Ford Health System. "Optimal treatment duration for MRSA-related pneumonia re-evaluated." ScienceDaily. www.sciencedaily.com/releases/2012/10/121020162448.htm (accessed November 26, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Wednesday, November 26, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com
From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

From Popcorn To Vending Snacks: FDA Ups Calorie Count Rules

Newsy (Nov. 25, 2014) The US FDA is announcing new calorie rules on Tuesday that will require everywhere from theaters to vending machines to include calorie counts. Video provided by Newsy
Powered by NewsLook.com
Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Daily Serving Of Yogurt Could Reduce Risk Of Type 2 Diabetes

Newsy (Nov. 25, 2014) Need another reason to eat yogurt every day? Researchers now say it could reduce a person's risk of developing type 2 diabetes. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins